Abstract
A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical adminsitration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0–1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.
Key words: Non-small cell lung cancer, Prognostic factors, Survival
References
- Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, Spitzer G, Umsawasdi T (1985) Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-123 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 3:176–183 [DOI] [PubMed] [Google Scholar]
- Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702–709 [DOI] [PubMed] [Google Scholar]
- Glatstein E, Makuch RW (1984) Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol 2:488–497 [DOI] [PubMed] [Google Scholar]
- Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95:414–420 [DOI] [PubMed] [Google Scholar]
- Klastersky J, Schuller JP, Weerts ND, Mairesse M, Libert P, Rocmans P, Michel J, Ferremans W (1983) Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell carcinoma: a clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 67:727–730 [PubMed] [Google Scholar]
- Longeval E, Klastersky J (1982) Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma: a study by the EORTC Lung Cancer Working Party (belgium). Cancer 50:2751–2756 [DOI] [PubMed] [Google Scholar]
- Mulshine JL, Glatstein E, Ruckdeschel JC (1986) Treatment of nonsmall cell lung cancer. J Clin Oncol 4:1704–1715 [DOI] [PubMed] [Google Scholar]
- O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patents with advanced non-small cell lung cancer treated with combination chemotherapy. J. Clin Oncol 4:1604–1614 [DOI] [PubMed] [Google Scholar]
- Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH (1985) Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, Generation V-A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3:72–79 [DOI] [PubMed] [Google Scholar]
- Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S (1986) A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4:14–22 [DOI] [PubMed] [Google Scholar]
- Saijo N, Shimizu E, Eguchi K, Shinkai T, Tominaga K, Shibuya M, Shimabukuro Z, Niitani H, Hoshi A (1983) Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung. Cancer Treat Rep 67:385–387 [PubMed] [Google Scholar]
- Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H (1985) Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 69:945–951 [PubMed] [Google Scholar]
- Shinkai T, Saijo N, Eguchi K, Sasaski Y, Tominaga K, Sakurai M, Suga J, Miyaoka H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A, Jett JR (1986) Cisplatin and vondesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res (Gann) 77:782–789 [PubMed] [Google Scholar]
- Simon R (1984) Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 68:185–192 [PubMed] [Google Scholar]
- Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32 [PubMed] [Google Scholar]